SOURCES SOUGHT
B -- Tianjin Study Center: A hospital-based case-control study of lymphoma in Asia (AsiaLymph) (CAS: 10512) - Statement of Work
- Notice Date
- 8/7/2013
- Notice Type
- Sources Sought
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions-Treatment and Support Branch, Bldg 244, Room 112, Frederick, Maryland, 21702
- ZIP Code
- 21702
- Solicitation Number
- HHSN-NIH-NCI-SBSS-TSB-34408-11
- Archive Date
- 8/29/2013
- Point of Contact
- Brenda Oberholzer, Phone: 301-228-4216, Brian Madgey, Phone: 301 624-8760
- E-Mail Address
-
oberholzerb@mail.nih.gov, brian.madgey@nih.gov
(oberholzerb@mail.nih.gov, brian.madgey@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Statement of Work Tianjin Study Center: A Hospital-Based Case-Control Study of Lymphoma in Asia (AsiaLymph) This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This requirement is assigned a code of 541990 in the North American Industry Classification System (NAICS), and the size standard for such requirements is $14 Million. The contribution of environmental, occupational and genetic factors to lymphoma has generated a series of novel, cutting edge findings in studies of Caucasians. However, the ability to follow-up, confirm and extend these observations has become limited in Western populations, due to the low prevalence and limited range of several important chemical exposures and the high to complete linkage disequilibrium between key candidate genetic loci. Therefore it is necessary to investigate populations that differ from Caucasians in both exposure patterns and underlying genetic structure. To this end, the National Cancer Institute is conducting a hospital-based case-control study of lymphoma in Eastern Asia (i.e. AsiaLymph). The major postulated risk factors for evaluation in this study are chemical exposures, genetic susceptibility, and infectious agents. A particularly noteworthy aspect of AsiaLymph is central pathology review with immunophenotyping, which will enable accurate analysis of findings by molecular and histologic subtypes. AsiaLymph should confirm and extend previous findings, and yield novel insights into the causes of lymphoma in both Asia and the West. The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), is anticipating to award a Firm-Fixed Price non-competitive purchase order to Tianjin Medical University, in Tianjin, China to coordinate study activities at 5 collaborating hospitals in Tianjin. The collaborating hospitals are Tianjin Medical University Institute and Hospital, Tianjin Medical University General Hospital, Tianjin First Center Hospital, Second Hospital of Tianjin Medical University, and Institute of Hematology & Blood Diseases Hospital. Contractor Requirements: The contractor shall conduct the following study tasks: 1. Ensure study coordinators and interviewers are properly trained. 2. Train and work with admission staff at each hospital to identify potential cases and controls as defined in the Study Protocol. 3. Train new study coordinators, interviewers and admission staff as necessary due to staff turnover. 4. Identify and enroll in the study 360 eligible lymphoma cases and 360 eligible controls, by the end of the period of performance. 5. Administer interview to enrolled cases and controls within 24 hours of enrollment. The interview will be provided in the Study Protocol, which will be provided by the NCI within 15 days of the award. This task must be completed by the end of the period of performance. 6. Collect and process blood and buccal cell specimens from each enrolled case and control within 24 hours of enrollment as specified in the Study Protocol, which will be provided by the NCI within 15 days of award. This task must be completed by the end of the period of performance; 7. Ship blood and buccal cells from enrolled cases and controls to NCI. Samples should be shipped by express mail, frozen on dry ice, using tracking. Full shipping instructions, including the address, will be contained in the Study Protocol, which will be provided by the NCI within 15 days of the award. This task must be completed for all enrolled cases and controls by the end of the period of performance. 8. Prepare 25 5 micron slides and 2 20 micron cuts from pathology specimens collected from enrolled cases. 9. Ship pathology specimens from enrolled cases to the Pathology Center every month during the period of performance. The Pathology center is located at the Queen Elizabeth Hospital in Hong Kong. Samples should be shipped overnight, using tracking. Full shipping instructions, including the address, will be contained in the Study Protocol, which will be provided by the NCI within 15 days of the award. This task must be completed for all enrolled cases by the end of the period of performance. 10. Track blood, buccal cell, and pathology specimens in a specimen tracking system provided by the NCI. Tracking includes recording the receipt of the samples from the enrolled cases and controls and the shipment of the samples. The online specimen tracking system will be made available within 15 days of the award. This task must be completed for all enrolled cases and controls by the end of the period of performance; 11. Upload interview data and participant information to the AsiaLymph Study Management System, every workday during the period of performance, for all cases and controls that were enrolled on that workday. The AsiaLymph Study Management system is an online database. The online Study Management system will be made available within 15 days of the award. This task must be completed for all enrolled cases by the end of the period of performance. 12. Compensate subjects for their participation in the study per guidelines in the Study Protocol. 13. Conduct monthly site-visits with each hospital to monitor enrollment, interview, specimen tracking, hospital records, and adherence to the Study Protocol. 14. Meet with NCI investigators in Hong Kong as planned by the study Coordinating Center. 15. Review study progress and monitor quality controls measures from each hospital bi-weekly. This includes collecting and reviewing: a. Enrollment data b. Questionnaires c. Biological Specimen tracking d. Hospital records 16. Report the following information monthly to the Coordinating Center at the University of Hong Kong and the NCI: a. Cases and controls enrolled b. Compensation paid to subjects c. Blood and buccal cell specimens collected and shipped d. Pathology specimens collected and shipped e. Interviews conducted f. Protocol violations To be deemed capable of providing the current need the offeror must submit a written capability statement. Organizations that submit capability statements in response to this notice will be evaluated against the following technical areas of experience and expertise: 1. Personnel/Experience: a. Proven organizational and past experience in recruiting patients, tissue and data collection, tissue storage and shipment. b. The offeror shall provide the name of the Principal Investigator, his/her professional qualifications and specific experience as a key investigator in recruiting patients and tissue collection and possessing sufficient authority to assure access to facilities and records required for the project. c. The offeror shall demonstrate that the proposed team and staff have previous successful experience in carrying out the requirements of the services stated herein. 2. Facilities: Adequacy of facilities for performing the Statement of Work. If any responsible source believes it can perform the requirements they may submit their capability statements via email (PDF format; 15 Page Limit, these pages exclude resumes) for consideration by NCI to Brenda Oberholzer, Contracting Officer, and Brian Madgey, Contract Specialist at the e-mail addresses provided by the response date. No collect calls or facsimile transmissions will be accepted. Respondents must include DUNS number, organization name, address, point of contact, and size and type of business (e.g., 8(a), HUBZONE, etc) pursuant to the applicable NAICS code. Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation(s). Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/FCRF2/HHSN-NIH-NCI-SBSS-TSB-34408-11/listing.html)
- Record
- SN03140784-W 20130809/130808000137-0392be6d51a4ed0c2e5aae5edfb773d6 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |